Related Experiment Video
Updated: Oct 29, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Abstract:
Interim results from the phase 3 HARMONi-GI1 trial demonstrate the first-in-class PD-1×VEGF bispecific antibody ivonescimab, combined with gemcitabine and cisplatin, significantly improved overall survival compared with durvalumab plus the same chemotherapy backbone in advanced biliary tract cancer. The regimen may represent a new standard of care for first-line advanced biliary tract cancer, though questions regarding patient selection and applicability beyond Chinese populations remain.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Treatment Resistant Cancers
Drugs that Stabilize Microtubules
Anthelminthic Agents